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Abstract 
 
Comparison of Healthcare Resource Utilization, Medication Use, and Costs among  
Heart Failure Patients with Reduced and Preserved Ejection Fraction 
 
Melody Tran, M.S.P.S. 
The University of Texas at Austin, 2016 
 
Supervisor: Karen L. Rascati 
Objectives: To compare health care resource utilization, medication use, and associated costs 
among heart failure (HF) patients with reduced versus preserved ejection fraction (EF). 
Methods: We included patients ≥ 18 years of age who had an inpatient admission with a 
primary discharge diagnosis of HF between October 1, 2011 and September 30, 2014 along with 
a recent EF measurement. Those with EF ≤ 40% were placed in the reduced EF group, and those 
with EF ≥ 50% were placed in the preserved EF group. Patients were excluded if they had an 
index length of stay (LOS) greater than 30 days, a prior heart transplant or LV atrial defibrillator. 
Baseline characteristics, healthcare utilization and associated costs, comorbidities, and 
medication use between the two groups were compared using inferential statistics and 
generalized linear models adjusted for clinical and demographic covariates were used to 
address the hypotheses, assessing the effect of EF group on utilization, costs, and medication 
use. 
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Results: A total of 380 HF patients were identified (54% female; mean [SD] age: 78.1 [12.0]), of 
which 116 (30%) had a reduced EF and 264 (69%) had a preserved EF. Those with preserved EF 
had a significantly greater proportion of females (60% vs 39%, p<0.001) and were older (mean 
[SD]: 79.0 [10.8] vs 76.0 [12.0] years, p=0.044). After adjusting for demographics, baseline 
utilization, and other clinical factors, EF group was not a significant predictor of any healthcare 
resource utilization or cost variable. Those with reduced EF had a higher prevalence of coronary 
heart disease (82% vs 62%, p<0.001) and cardiomyopathy (54% vs 15%, p<0.001) compared to 
those with preserved EF. Depression was more prevalent in HF patients with preserved EF (22% 
vs 11%, p=0.014) as compared to those with reduced EF. After controlling for demographics, 
baseline medication use, and other clinical characteristics, HF patients with reduced EF were 
shown to be less likely to have use of calcium channel blockers (OR: 0.380, 95% CI: 0.181-0.800, 
p=0.011). 
Conclusion: This study demonstrated that healthcare utilization and associated costs are similar 
between HF patients with reduced and preserved EF, thus HF can be considered a single entity 
in terms of overall resource use.  Findings also showed that HF patients with reduced EF have 
higher prevalence of coronary heart disease and cardiomyopathy, while having lower 
prevalence of depression. Those with reduced HF also had less use of calcium channel blockers. 
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Chapter 1: Literature Review 
Introduction 
A progressive and chronic condition often punctuated by acute episodes, heart failure 
(HF) is a complex syndrome caused by structural or functional abnormality that impairs the 
ability of the ventricle to fill with or eject blood.1 This impairment leads to reduced cardiac 
output, resulting in the cardinal clinical manifestations of HF: fatigue, shortness of breath, and 
often volume overload.2 Due to these symptoms, HF patients often have reduced functional 
capacity, resulting in decreased quality of life and frequently leading to hospitalization.3,4 
It was previously believed that reduced myocardial contractility, or systolic dysfunction, 
was the only disturbance in cardiac function responsible for HF; however, it is now known that 
a large proportion of patients with the HF syndrome have relatively normal systolic function. 
These patients have impairment of diastolic function due to slow left ventricular (LV) relaxation 
and increased stiffness.5,6 Historically, such HF patients with normal LV ejection fraction (LVEF) 
were classified as having diastolic HF, and those with severe dilation and significantly reduced 
LVEF as having systolic HF. Diastolic HF was previously thought to account for about one-third 
of HF patients, and its prognosis was considered to be more benign than systolic HF, with lower 
mortality and morbidity rate.7,8  
However, in the last decade, perspectives on how these syndromes are defined and 
their perceived burden have changed substantially. Because abnormalities of systolic and 
diastolic dysfunction can coexist in patients with HF, they are now characterized as HF with 
preserved EF (HFpEF) and HF with reduced EF (HFrEF). Also, in contrast to what was previously 
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known, recent studies have shown that prevalence of HF with preserved EF has increased to 
about half of patients with HF, with a prognosis similar to those with reduced EF.6,9-11  
As described in greater detail in Table 1.1, a reduced EF is defined as ≤ 40%, while a 
preserved EF is defined as ≥ 50%.12 EF is considered important in classification of HF because of 
differences in patient demographics, comorbid conditions, and response to treatment.12,13 For 
example, HF patients with a preserved EF are more likely to be older and female compared to 
those with a reduced EF.9,11,14 Also, compared to those with reduced EF, HF with preserved EF is 
associated with certain comorbidities, including hypertension, obesity, atrial fibrillation, 
diabetes, and anemia.11,15 Because of these differences in demographic and clinical 
characteristics, a better understanding of how the burden of these two clinical entities differ 
will help clinicians better manage their HF patients, as well as inform decision making related to 
resource allocation. 
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Table 1.1 Definitions of HF with reduced and preserved EF12 
Classification EF (%) Description 
Heart failure with 
reduced ejection 
fraction (HFrEF) 
≤ 40  Also referred to as systolic HF.  
 Randomized controlled trials have mainly enrolled 
patients with HFrEF, and it is only in these patients that 
efficacious therapies have been demonstrated to date. 
Heart failure with 
preserved 
ejection fraction 
(HFpEF) 
≥ 50  Also referred to as diastolic HF.  
 Several different criteria have been used to further define 
HFpEF.  
 The diagnosis of HFpEF is challenging because it is largely 
one of excluding other potential noncardiac causes of 
symptoms suggestive of HF.  
 To date, efficacious therapies have not been identified. 
HFpEF, 
borderline 
41 to 49  These patients fall into a borderline or intermediate 
group.  
 Their characteristics, treatment patterns, and outcomes 
appear similar to those of patients with HFpEF 
HFpEF, 
improved 
> 40  It has been recognized that a subset of patients with 
HFpEF previously had HFrEF. 
 These patients with improvement or recovery in EF may 
be clinically distinct from those with persistently 
preserved or reduced EF.  
 Further research is needed to better characterize these 
patients.  
EF, ejection fraction; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; 
and HFrEF, heart failure with reduced ejection fraction 
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Epidemiology 
HF is a leading cause of death in the United States (US), with 1 in every 9 deaths having 
HF as a contributing cause in 2013.4 With an estimated 5.7 million US adults currently affected 
by HF, projections show that the prevalence of HF will increase by almost 50% to over 8 million 
people by 2030.3 Risk factors for developing HF include male gender, less education, physical 
inactivity, cigarette smoking, being overweight, diabetes, hypertension, valvular heart disease, 
and coronary heart disease.16,17 In the well-known Framingham Heart Study sponsored by the 
National Heart, Lung, and Blood Institute (NHLBI), researchers found that there is a 20% lifetime 
risk of developing HF at 40 years of age.18 It has also been shown that that the incidence of HF 
doubles with each 10-year increase in age after 65 years in men, with the incidence rate tripling 
for women after age 65.19 
 With HF being the most common hospital discharge diagnosis in patients over age 65, a 
large proportion of HF patients are elderly, having multiple comorbid conditions that influence 
morbidity and mortality.4,20 Despite a decline in mortality rates over the last 50 years, the 
overall 5-year survival for HF patients is about 50%, with likelihood of death increasing with 
symptom severity.20-22 Sudden cardiac death occurs in about 40% of patients, with serious 
ventricular arrhythmias often implicated as the underlying cause.12,23 Evidence has shown that 
many factors (e.g., age, gender, EF, renal function, natriuretic peptide plasma concentrations, 
diabetes, extent of underlying coronary artery disease, blood pressure, HF etiology, and drug or 
device therapy) can affect the prognosis of HF patients.21,24 
Among patients with HF, recent studies have estimated that approximately 47% to 55% 
have a preserved EF.10,25-27 HF patients with preserved versus reduced ejection fraction have 
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distinct demographics and clinical characteristics. HF patients with a preserved EF are more 
likely to be older and female compared to those with reduced EF.9,11,14 In addition, those with 
preserved EF tend to have greater prevalence of certain comorbidities, including hypertension, 
obesity, atrial fibrillation, diabetes, and anemia compared to those with reduced EF.11,15 One 
study showed HF patients with a preserved EF had a higher risk of noncardiovascular death in 
comparison to those with reduced EF.22 Despite these differences, however, overall prognosis 
of both HF syndromes are similar, with studies showing comparable mortality rates between 
the two groups.9,15  
Disease Etiology and Pathogenesis  
HF is a progressive disorder that is initiated after an event damages the cardiac muscle 
or impairs its ability to contract. This event can be abrupt, as in a myocardial infarction (MI), or 
gradual, as in chronic pressure or volume overload. Although the etiologies of HF with 
preserved versus reduced EF differ, there is still some overlap in the origins of these two 
conditions.1,28 Common causes of HF are listed in Table 1.2.  
The most common cause of both HF with reduced and preserved EF is coronary artery 
disease (CAD), with almost 70% of HF cases resulting from this.15,29 CAD often leads to 
prolonged ischemia and eventually causes the irreversible death of myocardial cells, or MI. 
After an MI, the amount of cardiac muscle death affects the degree to which contractility is 
impaired. To maintain cardiac output, the body activates several compensatory mechanisms 
that allow patients to sustain LV function for a period of months to years, with patients 
remaining asymptomatic for some initial period of time.  
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Compensatory neurohormonal systems maintain cardiac output by retaining salt and 
water, and include the adrenergic nervous system, the renin-angiotensin-aldosterone system 
(RAAS), and the cytokine system.1 These systems are the main target of current 
pharmacotherapies for HF with reduced EF. In addition, to increase myocardial contractility, the 
remaining functional cardiac muscle compensates by undergoing hypertrophic remodeling, 
which leads to further injury of the heart.30  
In contrast to what is known about the pathogenesis of HF with reduced EF, the 
pathophysiology of HF with preserved EF is not well understood. Previously, diastolic 
dysfunction was considered to be the only mechanism responsible for the development of HF 
with preserved EF; however, a new paradigm suggests that non-cardiac mechanisms and 
comorbidities can drive myocardial dysfunction and remodeling in this disease.25,31 This 
incomplete understanding of the pathophysiology of HF with preserved EF is the reason for the 
lack of effective therapies for this condition to date. 
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Table 1.2: Common Etiologies of Heart Failure1 
Heart Failure with  
Reduced Ejection Fraction 
Heart Failure with  
Preserved Ejection Fraction 
Coronary artery disease 
 Myocardial infarction* 
 Myocardial ischemia* 
Chronic pressure overload 
 Hypertension* 
 Obstructive valvular disease* 
Chronic volume overload 
 Regurgitant valvular disease 
 Intracardiac (left-to-right) shunting 
 Extracardiac shunting 
Chronic lung disease 
 Cor pulmonale 
 Pulmonary vascular disorders 
Nonischemic dilated cardiomyopathy 
 Familial/genetic disorders 
 Infiltrative disorders* 
Toxic/drug-induced damage 
 Metabolic disorder* 
 Viral 
Chagas’ disease 
Disorders of rate and rhythm 
 Chronic bradyarrhythmias 
 Chronic tachyarrhythmias 
Pathologic hypertrophy 
 Primary (hypertrophic cardiomyopathies) 
 Secondary (hypertension) 
Aging 
Restrictive cardiomyopathy 
 Infiltrative disorders (amyloidosis, 
sarcoidosis) 
 Storage diseases (hemochromatosis) 
Fibrosis 
Endomyocardial disorders 
* Indicates conditions that can also lead to HF with preserved EF. 
Adapted from Mann 2015. 
 
Classification of Disease 
The presence and severity of HF have been classified by the American College of 
Cardiology Foundation (ACCF) and the American Heart Association (AHA), as well as the New 
York Heart Association (NYHA).23,32 The ACCF/AHA stages focus on development and worsening 
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of disease, which is reflective of the progressive nature of HF.23 Patients in the ACCF/AHA HF 
Stages A and B are at risk for developing heart failure, whereas Stage C and D patients have 
confirmed HF. 
The NYHA I-IV classification describes the patient’s exercise capacity and the 
symptomatic disease severity using subjective evaluation by the clinician.32 In contrast to the 
ACCF/AHA stages of HF, the NYHA classification does not assess disease progression, but rather 
severity of symptoms at a specific point in time. For example, the ACCF/AHA HF stage of a 
patient would not be able to improve from Stage C to Stage B, whereas the symptoms of the 
patient could fluctuate from NYHA class IV to I with diuretic therapy that improves volume 
overload. Both types of classifications are used together to guide evaluation and treatment of 
HF patients. Table 1.3 compares the differences between the two types of HF classification and 
demonstrates how they complement each other.  
  
9 
 
Table 1.3: Comparison of ACCF/AHA Stages of HF and NYHA Functional Classifications 
ACCF/AHA Stages of HF23 NYHA Functional Classification32 
A At high risk for HF but without 
structural heart disease or 
symptoms of HF 
None  
B Structural heart disease but 
without signs or symptoms of HF 
I No limitation of physical activity. 
Ordinary physical activity does not 
cause symptoms of HF 
C Structural heart disease with prior 
or current symptoms of HF 
I No limitation of physical activity. 
Ordinary physical activity does not 
cause symptoms of HF 
II Slight limitation of physical activity. 
Comfortable at rest, but ordinary 
physical activity results in symptoms 
of HF 
III Marked limitation of physical activity. 
Comfortable at rest, but less than 
ordinary activity causes symptoms of 
HF 
IV Unable to carry on any physical 
activity without symptoms of HF, 
or symptoms of HF at rest 
D Refractory HF requiring specialized 
interventions 
IV Unable to carry on any physical 
activity without symptoms of HF, 
or symptoms of HF at rest 
ACCF, American College of Cardiology Foundation; AHA, American Heart Association; HF, heart 
failure; and NYHA, New York Heart Association. 
 
Clinical Guidelines for Management of Heart Failure 
The ACCF and the AHA have collaborated to produce guidelines in the area of 
cardiovascular disease since 1980.12 According to these guidelines, current treatment goals in 
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HF aim to improve both survival and health-related quality of life (HRQoL) of patients. Figure 
1.1 depicts the evidence-based guideline-directed medical therapies recommended by the 
ACCF/AHA for each stage in the development of HF. For patients at risk for HF (Stages A and B), 
therapy focuses on treatment of HF risk factors, such as hypertension and diabetes. For Stage C, 
NYHA Class I-IV HFrEF, evidence-based therapies include an angiotensin converting enzyme 
inhibitor (ACEI) or angiotensin receptor blocker (ARB), and a beta blocker. Depending on their 
NYHA classification and ethnicity, patients should also receive loop diuretics, hydral nitrates, or 
aldosterone antagonists as appropriate. For patients with EF < 35%, cardiac resynchronization 
therapy (CRT) or an implantable cardioverter-defibrillator (ICD) is recommended.12 
 In contrast to their efficacy in HF patients with reduced EF, the abovementioned drugs 
were found to have neutral outcomes in those with preserved EF.33-41 As a result, guideline-
directed medical therapy for HF with preserved EF focuses only on treatment of symptomatic 
congestion and comorbidities such as hypertension, atrial fibrillation, coronary artery disease, 
and diabetes mellitus.12,42 
 Patients with advanced, refractory HF (Stage D) have recurrent hospitalizations despite 
guideline-directed medical therapy. In these patients who are considered near the end of their 
life, treatments include advance care measures, such as heart transplant or mechanical 
circulatory support, followed by palliative care and hospice. 
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Figure 1.1: Stages in the development of HF and recommended therapy by ACCF/AHA stage12 
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Burden of Illness 
Humanistic Burden 
Due to their significantly reduced functional capacity, HF patients have poorer HRQoL as 
compared with the general population,43 and even in comparison with patients suffering from 
other chronic diseases, such as chronic obstructive pulmonary disease, arthritis, diabetes,  and 
other coronary diseases.44-48 Factors that have been shown to have a negative influence on the 
HRQoL of patients with HF include disease severity and presence of comorbidities such as 
depression.44,49,50 Other demographic factors that can impact HRQoL in patients with HF include 
age, gender, socioeconomic status, professional status, marital status, and the absence of a 
supportive social network.43,44,51-53 
 Although current treatment goals in heart failure are to improve both survival and 
HRQoL, recommended therapies that have survival benefits have only modest positive effect 
(e.g., ACEIs) or no impact (e.g., beta blockers) on HRQoL. In contrast, some therapies that have 
been shown to improve HRQoL, such as inotropic agents, do not improve survival.54 
Economic Burden 
In 2012, HF in the US was estimated to cost a total of $30.7 billion, 68% of which was 
attributed to direct medical costs. This estimate includes the cost of health care services, 
medications, and productivity. By the year 2030, total costs of HF are projected to increase to 
$69.7 billion, which is more than double the current cost of HF. The proportion related to direct 
medical costs is also expected to increase to over 75% of total medical costs, to $53 billion.3 The 
greatest financial burden of treating chronic HF is attributed to hospitalizations, which costs 
between $12,000 to $31,000 per patient per hospitalization.55  
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A study comparing the 5-year medical costs between HF patients with reduced versus 
preserved EF found similar costs between the two groups ($49,128 vs $45,604), although HFrEF 
patients were found to have more cardiology encounters and cardiac procedures. In models 
accounting for comorbid conditions, the costs with normal and abnormal EF remained similar.56 
Clinical Burden 
Hospitalizations occur often after HF diagnosis, with about 83% of patients hospitalized 
at least once and 43% hospitalized at least 4 times.57 Dunlay et al found that of these 
hospitalizations, more than half were unrelated to cardiovascular causes. Among Medicare 
beneficiaries, the overall HF hospitalization rate declined substantially in the last decade, but at 
a lower rate for African American men.20 Data from the surveillance component of the 
Atherosclerosis Risk in Communities (ARIC) Study sponsored by the NHLBI found that in elderly 
patients (aged 55 years and older), the average incidence of HF hospitalization was 11.6 per 
1000 patients per year. Of the incident hospitalized HF events, 53% had reduced EF and 47% 
had preserved EF. The ARIC study also found that among HF hospitalizations, African American 
men had the highest proportion of HF hospitalizations with reduced EF (70%), while Caucasian 
women had the highest proportion of HF hospitalization with preserved EF (59%).58 After an HF 
hospitalization 1-year mortality was found to be about 30% and did not differ by race or sex. 
  A study in Olmsted County, MN showed that HF hospitalizations occurred more often 
among men and were similar in HF patients with reduced EF versus preserved EF. The study 
also found that, among those with HF, hospitalization rates for cardiovascular causes did not 
change over time, whereas those for noncardiovascular causes increased from 2000 to 2010.22 
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Study Objectives 
In recent years, the differences between HF with reduced versus preserved LVEF have 
been better understood. However, to date, there have only been therapies proven to be 
efficacious in HF patients with reduced EF,33-38 while there have been no trials that show 
improved outcomes for those with preserved EF.34,36,39-41 Nonetheless, there are ongoing 
clinical trials for new therapies that have the potential to be safe and effective in patients with 
HF with preserved EF.59 With the development of these novel and costly therapies targeting HF 
with preserved EF on the horizon, it is becoming important to understand the differences in 
burden of disease between those with reduced and preserved EF in order to make informed 
decisions related to resource allocation.  
As demonstrated in the previously reviewed literature, HF with reduced versus 
preserved EF are distinct clinical entities with differing etiologies and demographic 
characteristics. For this reason, common outcomes of HF, such as hospitalization and other 
healthcare resource utilization may occur at different rates. However, comparative outcome 
studies have been inconclusive, and evidence comparing health care resource utilization and 
medication use are limited.9,14,56,60-64 This study aims to compare health care resource 
utilization, medication use, and associated costs among HF patients with reduced versus 
preserved EF. Specific objectives and null hypotheses of this study include: 
1. To determine whether healthcare resource utilization, including inpatient, emergency 
department, and outpatient visits, differs between HF patients with reduced versus 
preserved EF. 
H01.1: The difference in number of inpatient admissions between HF patients 
with reduced and preserved EF is not statistically significant. 
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H01.2: The difference in number of inpatient hospital days between HF patients 
with reduced and preserved EF is not statistically significant. 
H01.3: The difference in number of primary care outpatient visits between HF 
patients with reduced and preserved EF is not statistically significant. 
H01.4: The difference in number of cardiology outpatient visits between HF 
patients with reduced and preserved EF is not statistically significant. 
H01.5: The difference in number of emergency department visits between HF 
patients with reduced and preserved EF is not statistically significant. 
2. To determine whether healthcare costs, including prescription, inpatient, and 
outpatient costs, differ between HF patients with reduced versus preserved EF. 
H02.1: The difference in prescription costs between HF patients with reduced 
and preserved EF is not statistically significant. 
H02.2: The difference in inpatient costs between HF patients with reduced and 
preserved EF is not statistically significant. 
H02.3: The difference in outpatient costs between HF patients with reduced and 
preserved EF is not statistically significant. 
H02.4: The difference in total overall costs between HF patients with reduced 
and preserved EF is not statistically significant. 
3. To determine whether prevalence of comorbidities differ between HF patients with 
reduced versus preserved EF. 
H03.1: The difference in prevalence of diabetes between HF patients with 
reduced and preserved EF is not statistically significant. 
H03.2: The difference in prevalence of dyslipidemia between HF patients with 
reduced and preserved EF is not statistically significant. 
H03.3: The difference in prevalence of hypertension between HF patients with 
reduced and preserved EF is not statistically significant. 
H03.4: The difference in prevalence of coronary heart disease between HF 
patients with reduced and preserved EF is not statistically significant. 
H03.5: The difference in prevalence of cardiomyopathy between HF patients with 
reduced and preserved EF is not statistically significant. 
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H03.6: The difference in prevalence of dysrhythmia between HF patients with 
reduced and preserved EF is not statistically significant. 
H03.7: The difference in prevalence of valvular heart disease between HF 
patients with reduced and preserved EF is not statistically significant. 
H03.8: The difference in prevalence of depression between HF patients with 
reduced and preserved EF is not statistically significant. 
H03.9: The difference in prevalence of tobacco use between HF patients with 
reduced and preserved EF is not statistically significant. 
H03.10: The difference in prevalence of alcohol/other drug use between HF 
patients with reduced and preserved EF is not statistically significant. 
4. To determine whether medication use differs between HF patients with reduced versus 
preserved EF. 
H04.1: The difference in anticoagulant use between HF patients with reduced 
and preserved EF is not statistically significant. 
H04.2: The difference in antiarrhythmic use between HF patients with reduced 
and preserved EF is not statistically significant. 
H04.3: The difference in antilipemic use between HF patients with reduced and 
preserved EF is not statistically significant. 
H04.4: The difference in cardiotonic use between HF patients with reduced and 
preserved EF is not statistically significant. 
H04.5: The difference in beta-blocker use between HF patients with reduced and 
preserved EF is not statistically significant. 
H04.6: The difference in calcium channel blocker use between HF patients with 
reduced and preserved EF is not statistically significant. 
H04.7: The difference in use of RAAS-inhibiting agents between HF patients with 
reduced and preserved EF is not statistically significant. 
H04.8: The difference in diuretic use between HF patients with reduced and 
preserved EF is not statistically significant. 
H04.9: The difference in number of unique drugs between HF patients with 
reduced and preserved EF is not statistically significant. 
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Chapter 2: Methodology 
Study Design and Data Source 
This was a retrospective, observational review of claims and electronic medical record 
(EMR) data. Data were extracted from the Scott & White Health Plan (SWHP), which covers 
over 250,000 lives and is part of an integrated delivery network in Central Texas that includes a 
network of hospitals, clinics, and pharmacies. Pharmacy and medical claims, along with patient 
enrollment and medical care data containing demographic information, were linked 
longitudinally to EMR data. Pharmacy claims contain details from all dispensed prescriptions, 
including the drug name, date and quantity dispensed, days supplied, and plan- and patient-
paid amounts. Medical claims provided detailed information on inpatient and outpatient 
services, including date and place of service, payments, procedure codes, and up to 5 
International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM) diagnosis 
codes per date of care.  
 The date of admission of first hospitalization with a primary discharge diagnosis of HF 
was referred to as the index date. A recent EF measurement from an echocardiogram was used 
to determine the patient cohort. Data were collected from one year prior to the index date 
through 1 year post-admission including: details of index admission, and healthcare resource 
utilization and costs. Collected variables are described in greater detail in the following 
sections. This study was approved by the University of Texas at Austin and the Baylor Scott & 
White Health institutional review boards following expedited review. 
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Sample Selection 
Patients at least 18 years of age with an inpatient admission with a primary discharge 
diagnosis of HF (ICD-9-CM 428.xx) between October 1, 2011 and September 30, 2014 were 
identified (fiscal years FY2012-FY2014). To be included in the study, patients had to be enrolled 
for 1 year prior to and at least 1 year after the index admission; the number of enrolled days 
was included as a covariate for patients with less than 2 full years of enrollment. In addition, 
patients were required to have a recent EF measurement from an echocardiogram to 
determine their placement into either EF group. Patients were excluded if they had an index 
length of stay (LOS) greater than 30 days, a prior heart transplant or LV atrial defibrillator.  
Study Variables 
 The following baseline data parameters were collected from the one-year time period 
prior to the index admission: age, gender, costs of care (costs to patient; costs to health plan), 
medication use, and comorbidities. Comorbidities at baseline were identified using appropriate 
ICD-9-CM and Current Procedural Terminology (CPT) codes from medical claims, and American 
Hospital Formulary System (AHFS) codes from pharmacy claims, as described in Table 2.1. 
Variables related to the index admission included the length of stay and the most recent EF 
measurement from an echocardiogram, as well as the lag time between EF assessment and 
admission. Data parameters collected during the follow-up period after index admission 
included the number of inpatient admissions, hospital days, outpatient visits, emergency 
department visits, pharmacy dispenses, and costs (i.e., inpatient, outpatient, pharmacy, and 
total costs). Pharmacy utilization was normalized to a 30-day supply, and included the number 
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of unique medications overall, and number of dispenses of specific medication classes as 
described in Table 2.2. 
 
Table 2.1: Diagnosis, Procedure, and Drug Codes used to Identify Comorbidities 
Comorbidity ICD-9-CM Codes CPT or AHFS Codes 
Coronary heart disease 
 
410.x to 414.x 
 
Stent placement: SG0291, C9600 to C6908; 
Coronary bypass surgery: S2205 to S2209 
Diabetes mellitus  250.xx 
 
 
Hypertension  401.x to 405.x Anti-hypertensive drugs: 242400, 242800, 
243204, 243208, 402800, 402808, 402810, 
402812, 402816, 402820, 402824 
Depression  
 
296.2 to 296.8, 
300.4, 309.1, and 
311 
 
Dyslipidemia  272.xx  
Valvular heart disease  424.0 to 424.3  
Cardiomyopathy  425.x  
Tobacco use disorder 305.1  
Cardiac dysrhythmias  427.x  
AHFS, American Hospital Formulary System;  CPT, Current Procedural Terminology; ICD-9-CM, 
International Classification of Diseases, Ninth Edition, Clinical Modification 
 
  
 20 
 
Table 2.2: AHFS Codes used to Identify Medication Classes 
Drug Class AHFS Code 
Anti-arrhythmics 240404 
Anti-hypertensives, renin-angiotensin-aldosterone system inhibitors 
Angiotensin II receptor antagonists 
Angiotensin-converting enzyme inhibitors 
Mineralocorticoid (aldosterone) antagonists  
Renin inhibitors  
 
243208 
243204 
243220 
243240 
Anti-hypertensives, other 
Hypotensive agents 
Central alpha-agonists 
Direct vasodilators 
Peripheral adrenergic inhibitors 
 
240800 
240816 
240820 
240832 
Anti-coagulants 201204 
Calcium channel blockers 
Dihydropyridines  
Calcium-channel blocking agents, misc.  
242800 
242808 
242892 
Beta-blockers 242400 
Cardiotonic agents (e.g. digoxin) 240408 
Diuretics 
Loop diuretics  
Potassium-sparing diuretics  
Osmotic diuretics 
Thiazide diuretics  
Thiazide-like diuretics 
402800 
402808 
402810, 402816 
402812 
402820 
402824 
Anti-lipemics 
Antilipemic agents, miscellaneous  
HMG-CoA reductase inhibitors  
Fibric acid derivatives 
Cholesterol absorption inhibitors  
Bile acid sequestrants  
240600 
240692 
240608 
240606 
240605 
240604 
AHFS, American Hospital Formulary System 
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Statistical Analysis 
Descriptive statistics for demographic characteristics, as well as for outcome variables 
were prepared. Continuous variables were reported as mean (standard deviation) or median 
(interquartile range) as appropriate, and categorical variables were reported as count 
(percentages). Baseline characteristics of HF patients with reduced versus preserved EF were 
compared using t-tests for continuous variables and chi-square tests for categorical variables. 
Generalized linear models weighted by months of eligibility and also adjusted for clinical and 
demographic covariates were used to address the hypotheses, assessing the effect of EF group 
on utilization, costs, and medication use. Outcomes included costs, count data on utilization 
and medication use, binary indicators of medication class use, and comorbidities.  
Appropriate transformations were applied to the cost data, which are typically right-
skewed and responsive to log-transform. Count data were analyzed by a Poisson model or 
related approach, depending on the distribution of the outcome, for example, negative 
binomial regression for over-dispersed data, the approach applied here based on the deviance 
factor. The binary outcomes were modeled by multivariable logistic regression. In the event the 
number of cases was too small to support all covariates, they were tested in a step-wise 
regression model to achieve a parsimonious adjusted model. All analyses were performed using 
SAS version 9.4, using the a priori alpha level of 0.05 for all statistical analyses. 
In models regressing the HR-EF group on outcomes (utilization, costs, and medication 
use) adjusting for clinical and demographic covariates, an estimated regression coefficient 
associated with the HFrEF indicator whose 95% confidence interval excludes zero (or, 95% CI of 
OR [OR] or incident rate ratio [IRR] excludes 1) were supportive of the hypotheses.  
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Chapter 3: Results 
Study Sample 
A total of 831 patients with an HF admission were identified during the study period, 380 of 
which met all inclusion/exclusion criteria. Table 3.1 reports the sample attrition for the study. 
Table 3.1: Sample Selection 
Selection Criteria n (%) 
Inpatient admission with primary diagnosis of heart failure 
between Oct 1, 2010 and Sept 30, 2015 
831 (100%) 
Index admission between Oct 1, 2011 to Sept 30, 2014 601 (72%) 
Index length of stay < 30 days 439 (53%) 
No heart transplant or LV atrial defibrillator 439 (53%) 
≥ 18 years old 438 (53%) 
Ejection fraction ≤ 40 or ≥ 50 380 (46%) 
Borderline ejection fraction (40 < EF < 50) 58 (7%) 
  
Baseline Demographics and Clinical Characteristics  
Table 3.2 provides demographics and clinical characteristics at baseline. Of the 380 HF 
patients meeting the selection criteria, 116 (31%) had a reduced EF and 264 (69%) had a 
preserved EF. Those with preserved EF had a significantly greater proportion of females (60% vs 
39%, p<0.001) and were older (mean [SD]: 79.0 [10.8] vs 76.0 [14.2] years, p=0.044). Patients 
with reduced EF had a longer length of stay compared to those with preserved EF (mean [SD]: 
7.2 [20.9] vs 4.1 [3.2] days, p=0.114), although the difference was not statistically significant.  
 23 
 
By definition, those with reduced EF had lower mean LVEF compared to those with 
preserved EF (mean [SD]:  27.5 [8.8] vs 61.8 [8.0], p<0.001). Overall, only 56% of patients had an 
EF measurement within 1 month of the index admission, with the mean (SD) time between the 
most recent EF measurement and the index HF admission of 112.5 (149.6) or 3.8 (5.0) months. 
 Some differences in baseline comorbidities between the two groups were observed. HF 
patients with preserved EF had a greater prevalence of hypertension (89% vs 82%, p=0.045) 
compared to those with reduced EF. On the other hand, those with reduced EF had a higher 
prevalence of coronary heart disease (66% vs 50%, p=0.004) and cardiomyopathy (25% vs 7%, 
p<0.001) compared to those with preserved EF. Differences in prevalence of other 
comorbidities at baseline were not statistically significant.  
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Table 3.2: Baseline Demographics and Clinical Characteristics 
  All (N=380) 
HF with Reduced 
EF (n=116) 
HF with Preserved 
EF (n=264) 
p-
value* 
Demographics         
Female, n 204 (54) 45 (39) 159 (60) <.001 
Age, years 78.1 (12.0) 76.0 (14.2) 79.0 (10.8) 0.044 
Index variables     
Index admission length of 
stay, days 
5.0 (11.9) 7.2 (20.9) 4.1 (3.2) 0.114 
Left ventricular EF, % 51.4 (17.8) 27.5 (8.8) 61.8 (8.0) <.001 
Time between index 
admission and EF 
measurement**, days 
112.5 (149.6) 100.7 (141.9) 117.6 (152.9) 0.145 
EF within 1 year 305 (80%) 97 (84%) 208 (78%) 0.242 
EF within 6 months 275 (72%) 90 (78%) 185 (70%) 0.114 
EF within 3 months 242 (64%) 76 (66%) 166 (63%) 0.289 
EF within 1 month 212 (56%) 67 (58%) 145 (55%) 0.303 
Comorbidities, n (%)         
Diabetes 177 (47%) 52 (45%) 125 (47%) 0.650 
Dyslipidemia 255 (67%) 77 (66%) 178 (67%) 0.842 
Hypertension 331 (87%) 95 (82%) 236 (89%) 0.045 
Coronary heart disease 210 (55%) 77 (66%) 133 (50%) 0.004 
Cardiomyopathy 47 (12%) 29 (25%) 18 (7%) <0.001 
Dysrhythmia 226 (59%) 70 (60%) 156 (59%) 0.819 
Valvular heart disease 80 (21%) 27 (23%) 53 (20%) 0.481 
Depression 61 (16%) 16 (14%) 45 (17%) 0.426 
Tobacco use 27 (7%) 6 (5%) 21 (8%) 0.331 
Alcohol/other drug use 14 (4%) 5 (4%) 9 (3%) 0.668 
Expressed as count (%) or mean (SD); EF, ejection fraction; HF, heart failure 
*Bivariate analyses included t-tests for continuous data and chi-square tests for categorical data 
**Truncated at 365 days 
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Healthcare Resource Utilization 
 Healthcare resource utilization at baseline is described in Table 3.3. Overall, 57% of HF 
patients had at least 1 inpatient admission at baseline, with 19% of patients having 5 or more 
admissions prior to the index event. Compared to those with preserved EF, those with reduced 
EF have greater inpatient hospital days (mean [SD]: 6.8 [13.8] vs 5.6 [10.4] days, p=0.925) and 
fewer outpatient primary care visits (mean [SD]: 10.8 [9.3] vs 13.5 [14.9] days, p=0.182) at 
baseline, although these differences were not statistically significant. HF patients with reduced 
EF were found to have significantly more cardiology visits at baseline compared to those with 
preserved EF (mean [SD]: 6.2 [8.3] vs 3.7 [5.1] days, p=0.006). Baseline inpatient admissions and 
emergency department visits were similar between the two groups.  
A majority (94%) of patients overall had at least 1 re-hospitalization in the year following 
the index admission, with 25% having 5 or more hospitalizations. As shown in Table 3.4, 
unadjusted bivariate analysis revealed that HF patients with reduced EF had more outpatient 
visits to the cardiologist (mean [SD]: 7.9 [7.4] vs 5.8 [7.8] days, p<0.001), but fewer outpatient 
primary care visits (mean [SD]: 18.3 [16.6] vs 20 [14.3] days, p=0.040). However, after adjusting 
for demographic, baseline utilization, and other clinical factors, EF group was not a significant 
predictor of any healthcare resource utilization variable (Tables 3.5 to 3.9). 
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Table 3.3: Baseline Healthcare Resource Utilization 
  All (N=380) 
HF with Reduced 
EF (n=116) 
HF with Preserved 
EF (n=264) 
p-
value* 
Covered days 349.7 (65.8) 352.3 (62) 348.6 (67.5) 0.618 
At least 1 inpatient 
admission 
218 (57%) 66 (57%) 152 (57%) 0.933 
Number of inpatient admissions     
1 68 (18%) 19 (16%) 49 (18%)  
2 31 (8%) 8 (7%) 23 (9%)  
3 27 (7%) 7 (6%) 20 (8%) 0.745 
4 18 (5%) 8 (7%) 10 (4%)  
More than 5 74 (19%) 24 (21%) 50 (19%)  
Inpatient admissions 2.5 (4.1) 2.5 (3.7) 2.5 (4.2) 0.860 
Inpatient hospital days 6.0 (11.5) 6.8 (13.8) 5.6 (10.4) 0.925 
Primary care visits 12.7 (13.5) 10.8 (9.3) 13.5 (14.9) 0.182 
Cardiology visits 4.5 (6.3) 6.2 (8.3) 3.7 (5.1) 0.006 
Emergency department 
visits 
1.3 (2.0) 1.3 (1.9) 1.4 (2.0) 0.673 
Expressed as mean (SD) or count (%); EF, ejection fraction; HF, heart failure 
*Bivariate analyses included t-tests for continuous data, chi-square test for categorical data, 
and Wilcoxon rank-sum test for ordinal data 
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Table 3.4: Healthcare Resource Utilization during 1-year Follow-Up Period 
  All (N=380) 
HF with  
Reduced EF 
(n=116) 
HF with  
Preserved EF 
(n=264) 
p-
value* 
Covered days 332.2 (92.2) 320.7 (101.9) 337.3 (87.4) 0.107 
At least 1 inpatient 
admission 
358 (94%) 107 (92%) 251 (95%) 0.351 
Number of inpatient admissions     
1 105 (28%) 28 (24%) 77 (29%)  
2 76 (20%) 18 (16%) 58 (22%)  
3 41 (11%) 13 (11%) 28 (11%) 0.235 
4 39 (10%) 13 (11%) 26 (10%)  
More than 5 97 (25%) 35 (30%) 62 (23%)  
Inpatient admissions 4.4 (6.5) 5.6 (9) 3.9 (5) 0.231 
Inpatient hospital days 8.8 (15.8) 11.9 (21.6) 7.4 (12.2) 0.085 
Primary care visits 19.5 (15) 18.3 (16.6) 20 (14.3) 0.040 
Cardiology  visits 6.6 (7.7) 7.9 (7.4) 5.8 (7.8) <0.001 
Emergency department 
visits 
2.3 (2.5) 2.1 (2.3) 2.3 (2.6) 0.792 
Expressed as mean (SD) or count (%); EF, ejection fraction; HF, heart failure 
*Bivariate analyses included t-tests for continuous data, chi-square test for categorical data, 
and Wilcoxon rank-sum test for ordinal data 
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Table 3.5: Results of Negative Binomial Regression - Predicting Number of Inpatient Admissions by 
Demographic and Clinical Variables 
  Estimate 
Wald Chi-
Square 
Incident 
Rate Ratio 
(IRR) 
95% CI of IRR p-
value 
Lower Higher 
HFrEF 0.211 3.310 1.235 0.984 1.549 0.069 
Inpatient 
admissions at 
baseline 
0.079 31.280 1.083 1.053 1.113 <0.001 
Lag between EF and 
admission 
0.000 0.340 1.000 1.000 1.001 0.560 
Covered days  0.000 0.080 1.000 0.999 1.002 0.776 
Female -0.125 1.310 0.883 0.713 1.093 0.252 
Age -0.023 25.540 0.977 0.968 0.986 <0.001 
CI, confidence interval; EF, ejection fraction; and HFrEF, heart failure with reduced ejection 
fraction 
 
Table 3.6: Results of Negative Binomial Regression - Predicting Inpatient Hospital Days by 
Demographic and Clinical Variables 
  Estimate 
Wald Chi-
Square 
Incident 
Rate Ratio 
(IRR) 
95% CI of IRR p-
value 
Lower Higher 
HFrEF 0.254 3.120 1.289 0.972 1.709 0.078 
Inpatient hospital 
days at baseline 
0.032 18.420 1.033 1.018 1.048 <0.001 
Lag between EF and 
admission 
0.000 0.100 1.000 0.999 1.001 0.748 
Covered days  0.001 1.630 1.001 0.999 1.003 0.202 
Female -0.150 1.280 0.861 0.664 1.116 0.259 
Age -0.031 28.360 0.969 0.958 0.981 <0.001 
CI, confidence interval; EF, ejection fraction; and HFrEF, heart failure with reduced ejection 
fraction 
 
 
 29 
 
Table 3.7: Results of Negative Binomial Regression - Predicting Primary Care Visits by Demographic 
and Clinical Variables 
  Estimate 
Wald Chi-
Square 
Incident 
Rate Ratio 
(IRR) 
95% CI of IRR p-
value 
Lower Higher 
HFrEF -0.088 1.110 0.916 0.778 1.078 0.291 
Primary care visits 
at baseline 
0.012 12.750 1.012 1.005 1.018 <0.001 
Lag between EF and 
admission 
-0.001 4.020 1.000 0.999 1.000 0.045 
Covered days  0.000 0.010 1.000 0.999 1.001 0.924 
Female -0.025 0.110 0.975 0.839 1.134 0.745 
Age -0.007 3.550 0.993 0.986 1.000 0.059 
CI, confidence interval; EF, ejection fraction; and HFrEF, heart failure with reduced ejection 
fraction 
 
Table 3.8: Results of Negative Binomial Regression - Predicting Cardiology Visits by Demographic 
and Clinical Variables 
  Estimate 
Wald Chi-
Square 
Incident 
Rate Ratio 
(IRR) 
95% CI of IRR p-
value 
Lower Higher 
HFrEF 0.163 2.340 1.177 0.955 1.451 0.126 
Cardiology visits at 
baseline 
0.039 19.330 1.040 1.022 1.058 <0.001 
Lag between EF and 
admission 
-0.001 4.000 0.999 0.999 1.000 0.046 
Covered days  0.001 2.360 1.001 1.000 1.003 0.124 
Female -0.188 3.510 0.829 0.681 1.009 0.061 
Age -0.017 14.190 0.983 0.974 0.992 <0.001 
CI, confidence interval; EF, ejection fraction; and HFrEF, heart failure with reduced ejection 
fraction 
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Table 3.9: Results of Negative Binomial Regression - Predicting Number of Emergency Department 
Visits by Demographic and Clinical Variables 
  Estimate 
Wald Chi-
Square 
Incident 
Rate Ratio 
(IRR) 
95% CI of IRR p-
value 
Lower Higher 
HFrEF -0.035 0.090 0.966 0.774 1.206 0.759 
Emergency department 
visits at baseline 
0.171 50.110 1.186 1.132 1.244 <0.001 
Lag between EF and 
admission 
0.000 0.070 1.000 0.999 1.001 0.798 
Covered days  0.000 0.320 1.000 0.998 1.001 0.574 
Female 0.030 0.080 1.030 0.838 1.266 0.778 
Age -0.006 1.710 0.994 0.985 1.003 0.190 
CI, confidence interval; EF, ejection fraction; HFpEF, heart failure with preserved ejection 
fraction; and HFrEF, heart failure with reduced ejection fraction 
 
Costs 
 Baseline inpatient costs (total, plan and patient costs) were significantly higher in those 
with reduced EF (mean [SD] total inpatient costs: $3,047 [$14,467] vs $1,648 [$8,014], p=0.042; 
plan paid inpatient costs: $2,833 [$14,114] vs $1,583 [$7,926], p=0.048; patient paid inpatient 
costs: $214 [$665] vs $65 [$266], p=0.048; Table 3.10). Other healthcare costs were similar 
between the two groups during the 1-year period prior to index admission (Table 3.11).  
Unadjusted analysis found that those with reduced EF had greater overall costs on 
average (mean [SD]: $23,782 [$101,155] vs $7,695 [$13,568], p=0.888; Table 3.12). However, 
after controlling for demographics and baseline costs, EF group was not found to be a 
significant predictor of any follow-up cost variables (Tables 3.13 to 3.165). 
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Table 3.10: Baseline Healthcare Costs 
Mean (SD), $ 
Median [IQR], $ 
All (N=380) 
HF with 
Reduced EF 
(n=116) 
HF with 
Preserved EF 
(n=264) 
p-
value* 
Total Overall Costs 
7,654 (15,530) 
4,313 [6,180] 
8,951 (19,602) 
4,503 [7,131] 
7,084 (13,359) 
4,281 [5,821] 
0.351 
Total Inpatient 
Costs 
2,075 (10,416) 
0 [1,566] 
3,047 (14,467) 
0 [1,844] 
1,648 (8,014) 
0 [990] 
0.042 
Costs to 
Health Plan 
1,965 (10,216) 
0 [1,208] 
2,833 (14,114) 
0 [1,678] 
1,583 (7,926) 
0 [746] 
0.048 
Costs to 
Patient 
111 (433) 
0 [0] 
214 (665) 
0 [0] 
65 (266) 
0 [0] 
0.014 
Total Outpatient 
Costs 
3,758 (8,045) 
1,934 [3,025] 
4,434 (10,666) 
1,958 [3,669] 
3,462 (6,575) 
1,911 [2,902] 
0.926 
Costs to Health 
Plan 
3,482 (7,691) 
1,786 [2,871] 
4,116 (10,305) 
1,734 [3,178] 
3,204 (6,210) 
1,793 [2,688] 
0.987 
Costs to Patient 
276 (642) 
45 [244] 
318 (674) 
67 [289] 
257 (628) 
35 [228] 
0.218 
Total Pharmacy 
Costs 
1,820 (2,340) 
925 [2,662] 
1,470 (2,202) 
670 [1,992] 
1,974 (2,385) 
1,073 [2,924] 
0.215 
Costs to Health 
Plan 
1,400 (1,990) 
572 [2,107] 
1,084 (1,869) 
424 [1,419] 
1,539 (2,029) 
763 [2,473] 
0.108 
Costs to 
Patient 
420 (592) 
205 [584] 
386 (587) 
163 [486] 
435 (594) 
219 [611] 
0.880 
EF, ejection fraction; HF, heart failure; IQR, interquartile range; SD, standard deviation 
*Bivariate analyses included t-tests for continuous data 
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Table 3.11: Healthcare Costs During 1-Year Follow-Up 
Mean (SD), $ 
Median [IQR], $ 
All (N=380) 
HF with 
Reduced EF 
(n=116) 
HF with 
Preserved EF 
(n=264) 
p-
value* 
Total Overall Costs 
12,606 (57,337) 
4,612 [7,167] 
23,782 (101,155) 
3,684 [7,986] 
7,695 (13,568) 
4,759 [6,604] 
0.888 
Total Inpatient Costs 
6,919 (52,342) 
0 [1,943] 
16,913 (92,612) 
0 [2,122] 
2,528 (11,586) 
0 [1,794] 
0.102 
Costs to Health 
Plan 
3,122 (7,953) 
1,548 [3,010] 
4,183 (13,378) 
1,486 [2,875] 
2,656 (3,491) 
1,602 [3,126] 
0.379 
Costs to 
Patient 
236 (668) 
30 [190] 
280 (595) 
68 [253] 
216 (698) 
22 [162] 
0.196 
Total Outpatient 
Costs 
3,358 (8,196) 
1,723 [3,256] 
4,462 (13,632) 
1,651 [3,061] 
2,873 (3,843) 
1,740 [3,325] 
0.423 
Costs to Health 
Plan 
1,843 (5,087) 
608 [2,337] 
1,979 (7,493) 
303 [1,319] 
1,783 (3,569) 
797 [2,488] 
0.113 
Costs to Patient 
486 (822) 
218 [648] 
427 (858) 
202 [483] 
511 (807) 
233 [704] 
0.770 
Total Pharmacy 
Costs 
2,328 (5,672) 
907 [2,832] 
2,406 (8,075) 
511 [1,894] 
2,294 (4,225) 
1,130 [3,239] 
0.225 
Costs to Health 
Plan 
6,753 (52,113) 
0 [1,742] 
16,667 (92,313) 
0 [2,013] 
2,397 (11,175) 
0 [1,635] 
0.116 
Costs to 
Patient 
166 (658) 
0 [0] 
246 (694) 
0 [0] 
131 (639) 
0 [0] 
0.052 
EF, ejection fraction; HF, heart failure; IQR, interquartile range; SD, standard deviation 
*Bivariate analyses included t-tests for continuous data 
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Table 3.12: Results of Linear Regression: Predicting Total Overall Costs by Demographic and Clinical 
Variables 
Variable 
(Reference Group) 
Estimate Standard Error t-value p-value 
HFrEF (HFpEF) 0.097 0.176 0.550 0.582 
Log of baseline total 
overall costs 
0.896 0.036 24.670 <0.001 
Lag between EF and 
admission 
-0.001 0.001 -1.530 0.128 
Covered days -0.002 0.001 -1.800 0.072 
Female (Male) 0.302 0.164 1.840 0.067 
Age -0.025 0.007 -3.690 <0.001 
CI, confidence interval; EF, ejection fraction; HFpEF, heart failure with preserved ejection 
fraction; and HFrEF, heart failure with reduced ejection fraction 
 
 
Table 3.13: Results of Linear Regression: Predicting Inpatient Costs by Demographic and Clinical 
Variables 
Variable 
(Reference Group) 
Estimate Standard Error t-value p-value 
HFrEF (HFpEF) 0.443 0.445 1.000 0.320 
Log of baseline 
inpatient costs 
0.484 0.051 9.540 <0.001 
Lag between EF and 
admission 
0.002 0.001 1.170 0.243 
Covered days 0.002 0.003 0.730 0.464 
Female (Male) 0.467 0.414 1.130 0.260 
Age -0.009 0.017 -0.550 0.583 
CI, confidence interval; EF, ejection fraction; HFpEF, heart failure with preserved ejection 
fraction; and HFrEF, heart failure with reduced ejection fraction 
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Table 3.14: Results of Linear Regression: Predicting Outpatient Costs by Demographic and Clinical 
Variables 
Variable 
(Reference Group) 
Estimate Standard Error t-value p-value 
HFrEF (HFpEF) -0.281 0.220 -1.270 0.203 
Log of baseline 
outpatient costs 
0.751 0.044 17.150 <0.001 
Lag between EF and 
admission 
-0.001 0.001 -2.220 0.027 
Covered days -0.001 0.002 -0.600 0.550 
Female (Male) 0.295 0.206 1.430 0.153 
Age -0.029 0.009 -3.390 0.001 
EF, ejection fraction; HFpEF, heart failure with preserved ejection fraction; and HFrEF, heart 
failure with reduced ejection fraction 
 
 
Table 3.15: Results of Linear Regression: Predicting Pharmacy Costs by Demographic and Clinical 
Variables 
Variable 
(Reference Group) 
Estimate Standard Error t-value p-value 
HFrEF (HFpEF) -0.136 0.237 -0.570 0.567 
Log of baseline 
pharmacy costs 
0.873 0.031 27.830 <0.001 
Lag between EF and 
admission 
-0.001 0.001 -1.400 0.161 
Covered days -0.001 0.002 -0.840 0.400 
Female (Male) 0.159 0.223 0.710 0.477 
Age -0.026 0.009 -2.870 0.004 
EF, ejection fraction; HFpEF, heart failure with preserved ejection fraction; and HFrEF, heart 
failure with reduced ejection fraction 
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Comorbid Conditions 
Table 3.16 compares comorbidities between the two groups during the follow up 
period. Following the baseline trend, those with reduced EF had a higher prevalence of 
coronary heart disease (82% vs 62%, p<0.001) and cardiomyopathy (54% vs 15%, p<0.001) 
compared to those with preserved EF. Depression was more prevalent in HF patients with 
preserved EF (22% vs 11%, p=0.014) as compared to those with reduced EF. Differences in 
prevalence of other comorbidities of interest were not statistically significant. 
Table 3.16: Comorbid Conditions During 1-Year Follow Up 
  
All 
(N=380) 
HF with Reduced 
EF (n=116) 
HF with Preserved 
EF (n=264) 
p-value 
Diabetes 171 (45%) 48 (41%) 123 (47%) 0.347 
Dyslipidemia 253 (67%) 78 (67%) 175 (66%) 0.856 
Hypertension 349 (92%) 103 (89%) 246 (93%) 0.150 
Coronary heart disease 259 (68%) 95 (82%) 164 (62%) <0.001 
Cardiomyopathy 101 (27%) 63 (54%) 38 (14%) <0.001 
Dysrhythmia 287 (76%) 90 (78%) 197 (75%) 0.536 
Valvular heart disease 125 (33%) 44 (38%) 81 (31%) 0.166 
Depression 71 (19%) 13 (11%) 58 (22%) 0.013 
Tobacco use 31 (8%) 9 (8%) 22 (8%) 0.851 
Alcohol/other drug use 13 (3%) 3 (3%) 10 (4%) 0.553 
Expressed as count (%); EF, ejection fraction; HF, heart failure 
*Unadjusted bivariate analyses included chi-square tests for categorical data 
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Medication Use 
As shown in Table 3.17, the reduced EF group had a greater proportion of patients with 
antiarrhythmic use (16% vs 8%, p=0.035), but fewer patients with calcium-channel blocker use 
(19% vs 37%, p=0.001) at baseline. The proportion of patients using other medications of 
interest at baseline was similar between the two groups. The number of unique medications 
used by each group was also similar (mean [SD]: 9.4 [8.1] vs 10.3 [8.1], p=0.145).  
Among those on a medication, unadjusted bivariate analysis revealed that those with 
preserved EF have a greater number of antiarrhythmic (mean [SD] 30-day fills: 7.2 [3.4] vs 4.0 
[3.7], p=0.003) and antilipemic (mean [SD] 30-day fills: 9.1 [3.3] vs 6.9 [4], p=0.001) 
prescriptions during 1-year follow-up (Table 3.18). A greater proportion of those with preserved 
EF had calcium channel blocker use (30% vs 11%, p<0.001). After controlling for demographics, 
baseline medication use, and other clinical characteristics, logistic regression revealed that HF 
patients with reduced EF were less likely to have use of calcium channel blockers (Table 3.20; 
OR: 0.380, 95% CI: 0.181-0.800, p=0.011). EF group was not a significant predictor of 
medication use in any of the other drug classes of interest (Tables 3.21 to 3.29). 
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Table 3.17: Medication Use at Baseline by Drug 
  All (N=380) 
HF with 
Reduced EF 
(n=116) 
HF with 
Preserved EF 
(n=264) 
p-
value* 
Number of unique 
medications, mean (SD) 
10.0 (8.1) 9.4 (8.1) 10.3 (8.1) 0.145 
Medication Use     
Anticoagulants 85 (22) 23 (20) 62 (23) 0.441 
Antiarrhythmics 40 (10) 18 (16) 22 (8) 0.035 
Antilipemics 179 (47) 51 (44) 128 (48) 0.435 
Cardiotonics 37 (10) 15 (13) 22 (8) 0.160 
Beta-blockers 211 (55) 63 (54) 148 (56) 0.781 
Calcium channel blockers 119 (31) 22 (19) 97 (37) 0.001 
RAAS-inhibiting agents 193 (51) 62 (53) 131 (49) 0.471 
Other antihypertensives 32 (8) 5 (4) 27 (10) 0.057 
Diuretics 55 (14) 17 (14) 39 (15) 0.834 
Expressed as count of patients on a medication (%), unless otherwise specified; EF, ejection 
fraction; HF, heart failure; RAAS, renin-angiotensin-aldosterone system 
*Bivariate analyses included t-tests for continuous data and chi-square tests for categorical 
data 
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Table 3.18: Medication Use during 1-Year Follow Up 
  All (N=380) 
HF with 
Reduced EF 
(n=116) 
HF with 
Preserved EF 
(n=264) 
p-
value* 
Anticoagulants 87 (23) 25 (22) 62 (23) 0.693 
Antiarrhythmics 44 (12) 19 (16) 25 (9) 0.051 
Antilipemics 173 (45) 46 (40) 127 (48) 0.136 
Cardiotonics 44 (12) 17 (15) 27 (10) 0.209 
Beta-blockers 221 (58) 64 (55) 157 (59) 0.459 
Calcium channel blockers 93 (24) 13 (11) 80 (30) <0.001 
RAAS-inhibiting agents 214 (56) 67 (58) 147 (55) 0.679 
Other antihypertensives 40 (10) 9 (8) 31 (12) 0.248 
Diuretics 245 (64) 77 (66) 168 (63) 0.576 
Expressed as count of patients on a medication (%); EF, ejection fraction; HF, heart failure; 
RAAS, renin-angiotensin-aldosterone system 
*Bivariate analyses included chi-square tests for categorical data 
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Table 3.19: Baseline Number of Prescriptions Among Patients on a Medication 
  All (N=380) 
HF with  
Reduced EF  
HF with  
Preserved EF  
p-
value* 
Anticoagulants 6.9 (4.1) 7 (4.2) 6.8 (4) 0.690 
Antiarrhythmics 7 (4.1) 6 (4.3) 7.7 (3.9) 0.248 
Antilipemics 9 (3.4) 8.1 (3.7) 9.3 (3.3) 0.017 
Cardiotonics 7.9 (3.9) 7 (4) 8.6 (3.8) 0.398 
Beta-blockers 8.9 (3.7) 8.4 (3.8) 9.1 (3.7) 0.093 
Calcium channel blockers 8.6 (3.7) 7.3 (3.9) 8.9 (3.6) 0.090 
RAAS-inhibiting agents 8.7 (3.7) 8.4 (3.6) 8.8 (3.7) 0.343 
Other antihypertensives 5.8 (4) 3.8 (4.8) 6.2 (3.8) 0.166 
Diuretics 7.8 (3.8) 7.3 (3.8) 8 (3.8) 0.211 
Expressed as mean number of 30-day fills (SD); EF, ejection fraction; HF, heart failure; RAAS, 
renin-angiotensin-aldosterone system 
*Bivariate analyses included Kruskal-Wallis tests for ordinal data. 
 
Table 3.20: Number of Prescriptions Among Patients on a Medication during 1-year Follow-Up 
  All (N=380) 
HF with  
Reduced EF  
HF with  
Preserved EF 
p-
value* 
Anticoagulants 7.5 (3.9) 7.9 (3.8) 7.4 (3.9) 0.612 
Antiarrhythmics 5.8 (3.8) 4 (3.7) 7.2 (3.4) 0.003 
Antilipemics 8.5 (3.6) 6.9 (4) 9.1 (3.3) 0.001 
Cardiotonics 6.8 (4) 5.8 (3.9) 7.3 (4) 0.216 
Beta-blockers 7.9 (3.7) 7.6 (3.6) 8 (3.7) 0.300 
Calcium channel blockers 6.7 (4.1) 5.5 (4.4) 6.8 (4.1) 0.191 
RAAS-inhibiting agents 8 (4) 8 (4) 8 (4) 0.974 
Other antihypertensives 6 (4.2) 6 (3.2) 6 (4.4) 0.832 
Diuretics 7.6 (4) 7 (4.2) 7.8 (3.8) 0.208 
Expressed as mean number of 30-day fills (SD); EF, ejection fraction; HF, heart failure; RAAS, 
renin-angiotensin-aldosterone system 
*Bivariate analyses included Kruskal-Wallis tests for ordinal data 
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Table 3.21: Results of Logistic Regression - Predicting Number of Unique Medications by 
Demographic and Clinical Variables 
  Estimate 
Wald Chi-
Square 
Incident 
Rate Ratio 
(IRR) 
95% CI of IRR 
p-value 
Lower Higher 
HFrEF 0.051 0.700 1.052 0.935 1.184 0.402 
Unique medications at 
baseline 
0.115 584.060 1.122 1.111 1.132 <0.001 
Lag between EF and 
admission 
0.000 0.310 1.000 1.000 1.000 0.579 
Covered days 0.000 0.200 1.000 0.999 1.001 0.653 
Female -0.001 0.000 0.999 0.897 1.113 0.990 
Age 0.003 1.950 1.003 0.999 1.008 0.162 
CI, confidence interval; EF, ejection fraction; HFpEF, heart failure with preserved ejection 
fraction; and HFrEF, heart failure with reduced ejection fraction 
 
 
Table 3.22: Results of Logistic Regression - Predicting Anticoagulant Use by Demographic and 
Clinical Variables 
  Estimate 
Wald Chi-
Square 
Odds 
Ratio 
95% CI of  
Odds Ratio p-value 
Lower Higher 
HFrEF 0.068 3.499 1.070 0.549 2.088 0.842 
Anticoagulant use at 
baseline 
3.067 0.040 21.483 11.626 39.699 <0.001 
Lag between EF and 
admission 
0.000 95.853 1.000 0.999 1.000 0.550 
Covered days  0.000 0.357 1.000 0.999 1.000 0.722 
Female 0.215 0.127 1.240 0.669 2.298 0.494 
Age -0.002 0.467 0.998 0.971 1.025 0.862 
CI, confidence interval; EF, ejection fraction; and HFrEF, heart failure with reduced ejection 
fraction 
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Table 3.23: Results of Logistic Regression - Predicting Antiarrhythmic Use by Demographic and 
Clinical Variables 
  Estimate 
Wald Chi-
Square 
Odds 
Ratio 
95% CI of  
Odds Ratio p-value 
Lower Higher 
HFrEF 0.085 0.034 1.088 0.444 2.666 0.853 
Antiarrhythmic use at 
baseline 
4.030 71.815 56.232 22.144 142.798 <0.001 
Lag between EF and 
admission 
-0.001 1.096 0.999 0.998 1.000 0.295 
Covered days 0.000 1.027 1.000 0.999 1.000 0.311 
Female -0.448 0.979 0.639 0.263 1.552 0.322 
Age -0.023 1.893 0.977 0.946 1.010 0.169 
CI, confidence interval; EF, ejection fraction; and HFrEF, heart failure with reduced ejection 
fraction 
 
 
 
Table 3.24: Results of Logistic Regression - Predicting Antilipemic Use by Demographic and Clinical 
Variables 
  Estimate 
Wald Chi-
Square 
Odds 
Ratio 
95% CI of  
Odds Ratio p-value 
Lower Higher 
HFrEF -0.626 3.115 0.535 0.267 1.072 0.078 
Antilipemic use at 
baseline 
4.074 144.264 58.766 30.230 114.238 <0.001 
Lag between EF and 
admission 
-0.001 3.384 0.999 0.999 1.000 0.066 
Covered days -0.001 2.930 1.000 0.999 1.000 0.087 
Female -0.160 0.233 0.852 0.445 1.631 0.629 
Age -0.021 2.464 0.980 0.955 1.005 0.117 
CI, confidence interval; EF, ejection fraction; and HFrEF, heart failure with reduced ejection 
fraction 
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Table 3.25: Results of Logistic Regression - Predicting Cardiotonic Use by Demographic and Clinical 
Variables 
  Estimate 
Wald Chi-
Square 
Odds 
Ratio 
95% CI of  
Odds Ratio p-value 
Lower Higher 
HFrEF 0.365 0.675 1.441 0.603 3.445 0.411 
Cardiotonic use at 
baseline 
3.747 71.852 42.378 17.820 100.781 <0.001 
Lag between EF and 
admission 
0.000 0.410 1.000 0.999 1.001 0.522 
Covered days 0.000 0.017 1.000 0.999 1.001 0.897 
Female 0.217 0.249 1.242 0.530 2.910 0.618 
Age 0.006 0.128 1.007 0.971 1.043 0.720 
CI, confidence interval; EF, ejection fraction; and HFrEF, heart failure with reduced ejection 
fraction 
 
 
 
Table 3.26: Results of Logistic Regression - Predicting Beta Blocker Use by Demographic and 
Clinical Variables 
  Estimate 
Wald Chi-
Square 
Odds 
Ratio 
95% CI of  
Odds Ratio p-value 
Lower Higher 
HFrEF -0.138 0.251 0.871 0.508 1.493 0.616 
Beta blocker use at 
baseline 
2.521 94.919 12.439 7.491 20.655 <0.001 
Lag between EF and 
admission 
0.000 0.004 1.000 0.999 1.001 0.950 
Covered days 0.000 2.940 1.000 0.999 1.000 0.086 
Female 0.523 4.036 1.687 1.013 2.808 0.045 
Age -0.018 2.953 0.982 0.962 1.003 0.086 
CI, confidence interval; EF, ejection fraction; and HFrEF, heart failure with reduced ejection 
fraction 
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Table 3.27: Results of Logistic Regression - Predicting Calcium Channel Blocker Use by 
Demographic and Clinical Variables 
  Estimate 
Wald Chi-
Square 
Odds 
Ratio 
95% CI of  
Odds Ratio p-value 
Lower Higher 
HFrEF -0.966 6.493 0.380 0.181 0.800 0.011 
Calcium channel 
blocker use at baseline 
2.826 78.914 16.877 9.047 31.484 <0.001 
Lag between EF and 
admission 
0.000 1.593 1.000 0.999 1.000 0.207 
Covered days 0.000 0.966 1.000 0.999 1.000 0.326 
Female 0.452 1.882 1.572 0.824 3.001 0.170 
Age -0.023 3.165 0.977 0.953 1.002 0.075 
CI, confidence interval; EF, ejection fraction; and HFrEF, heart failure with reduced ejection 
fraction 
 
 
Table 3.28: Results of Logistic Regression - Predicting Use of RAAS-inhibiting Agents by 
Demographic and Clinical Variables 
  Estimate 
Wald Chi-
Square 
Odds 
Ratio 
95% CI of  
Odds Ratio p-value 
Lower Higher 
HFrEF 0.045 0.029 1.046 0.620 1.763 0.866 
RAAS-inhibiting agent 
use at baseline 
2.129 77.323 8.404 5.229 13.506 <0.001 
Lag between EF and 
admission 
0.000 1.169 1.000 0.999 1.000 0.280 
Covered days 0.000 0.673 1.000 1.000 1.001 0.412 
Female 0.390 2.460 1.477 0.907 2.403 0.117 
Age -0.019 3.545 0.981 0.962 1.001 0.060 
CI, confidence interval; EF, ejection fraction; and HFrEF, heart failure with reduced ejection 
fraction; RAAS, renin-angiotensin-aldosterone system 
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Table 3.29: Results of Logistic Regression - Predicting Use of Diuretics by Demographic and Clinical 
Variables 
  Estimate 
Wald Chi-
Square 
Odds 
Ratio 
95% CI of  
Odds Ratio p-value 
Lower Higher 
HFrEF 0.254 0.852 1.289 0.752 2.208 0.356 
Diuretic use at baseline 2.131 71.874 8.424 5.147 13.787 <0.001 
Lag between EF and 
admission 
0.000 0.415 1.000 0.999 1.000 0.520 
Covered days 0.000 2.868 1.000 1.000 1.001 0.090 
Female 0.424 2.773 1.529 0.928 2.519 0.096 
Age -0.013 1.708 0.987 0.967 1.007 0.191 
CI, confidence interval; EF, ejection fraction; and HFrEF, heart failure with reduced ejection 
fraction 
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Summary of Results 
 Results for all hypotheses tested are reported in Table 3.30. Healthcare resource 
utilization (Objective 1) and associated costs (Objective 2) were not found to be statistically 
different compared between those with reduced and preserved EF. Those with reduced EF have 
higher prevalence of coronary heart disease and cardiomyopathy (Objective 3), and less calcium 
channel blocker use (Objective 4). 
 
Table 3.30: Results of Hypotheses Testing 
Objectives and Alternate Hypotheses (H1) Result 
Objective 1 
To determine whether healthcare resource utilization differs between HF patients with 
reduced and preserved EF. 
H11.1: The number of inpatient admissions of HF patients with reduced EF 
is greater than that of those with preserved EF.  
Rejected 
H11.2: The number of inpatient hospital days of HF patients with reduced 
EF is greater than that of those with preserved EF.  
Rejected 
H11.3: The number of primary care outpatient visits of HF patients with 
reduced EF is greater than that of those with preserved EF.  
Rejected 
H11.4: The number of outpatient visits to a cardiologist in HF patients with 
reduced EF is greater than that of those with preserved EF.  
Rejected 
H11.5: The number of emergency department visits in HF patients with 
reduced EF is greater than that of those with preserved EF.  
Rejected 
Objective 2 
To determine whether healthcare costs differ between HF patients with reduced and 
preserved EF. 
H12.1: The prescription costs of HF patients with reduced EF will be higher 
than in those with preserved EF.  
Rejected 
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Table 3.30: Results of Hypotheses Testing (continued)  
Objectives and Alternate Hypotheses (H1) Result 
H12.2: The inpatient costs of HF patients with reduced EF will be higher 
than in those with preserved EF.  
Rejected 
H12.3: The outpatient costs of HF patients with reduced EF will be higher 
than in those with preserved EF.  
Rejected 
H12.4: The total overall costs of HF patients with reduced EF will be higher 
than in those with preserved EF.  
Rejected 
Objective 3 
To determine whether prevalence of comorbidities differ between HF patients with reduced 
and preserved EF. 
H13.1: The prevalence of diabetes in HF patients with reduced EF will be 
significantly higher than in those with preserved EF.  
Rejected 
H13.2: The prevalence of dyslipidemia in HF patients with reduced EF will 
be significantly higher than in those with preserved EF.  
Rejected 
H13.3: The prevalence of hypertension in HF patients with reduced EF will 
be significantly higher than in those with preserved EF.  
Rejected 
H13.4: The prevalence of coronary heart disease in HF patients with 
reduced EF will be significantly higher than in those with preserved EF.  
Failed to reject 
H13.5: The prevalence of cardiomyopathy in HF patients with reduced EF 
will be significantly higher than in those with preserved EF.  
Failed to reject 
H13.6: The prevalence of dysrhythmia in HF patients with reduced EF will 
be significantly higher than in those with preserved EF.  
Rejected 
H13.7: The prevalence of valvular heart disease in HF patients with 
reduced EF will be significantly higher than in those with preserved EF.  
Rejected 
H13.8: The prevalence of depression in HF patients with preserved EF will 
be significantly higher than in those with reduced EF.  
Failed to reject 
H13.9: The prevalence of tobacco use in HF patients with reduced EF will 
be significantly higher than in those with preserved EF.  
Rejected 
H13.10: The prevalence of alcohol/other drug use in HF patients with 
reduced EF will be significantly higher than in those with preserved EF.  
Rejected 
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Table 3.30: Results of Hypotheses Testing (continued) 
Objectives and Alternate Hypotheses (H1) Result 
Objective 4 
To determine whether medication use differs differ between HF patients with reduced and 
preserved EF. 
H14.1: The use of anticoagulants in HF patients with reduced EF will be 
significantly higher than in those with preserved EF.  
Rejected 
H14.2: The use of antiarrhythmics in HF patients with reduced EF will be 
significantly lower than in those with preserved EF.  
Rejected 
H14.3: The use of antilipemics in HF patients with reduced EF will be 
significantly lower than in those with preserved EF.  
Rejected 
H14.4: The use of cardiotonics in HF patients with reduced EF will be 
significantly higher than in those with preserved EF.  
Rejected 
H14.5: The use of beta-blockers in HF patients with reduced EF will be 
significantly higher than in those with preserved EF.  
Rejected 
H14.6: The use of calcium channel blockers in HF patients with reduced EF 
will be significantly lower than in those with preserved EF.  
Failed to reject 
H14.7: The use of RAAS-inhibiting agents in HF patients with reduced EF 
will be significantly higher than in those with preserved EF.  
Rejected 
H14.8: The use of diuretics in HF patients with reduced EF will be 
significantly higher than in those with preserved EF.  
Rejected 
H14.9: The number of unique drugs used in HF patients with reduced EF 
will be significantly higher than in those with preserved EF.  
Rejected 
EF, ejection fraction; and RAAS, renin-angiotensin-aldosterone system. 
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Chapter 4: Discussion and Conclusion 
Discussion 
The purpose of this study was to assess differences in healthcare resource utilization 
and associated costs between HF patients with reduced versus preserved EF. It also sought to 
describe differences in medication use and prevalence of comorbidities between the two 
groups. Although a greater proportion (70%) of the HF patients in this study had a preserved EF 
compared to about 50% as described in the literature,10,25-27 our findings support current 
evidence that those with a preserved EF are more likely to be female and older compared to 
the group with reduced EF.9,11,14 
EF measurements are important in classifying HF patients due to differences in patient 
demographics, comorbidities, and response to therapies; thus it is recommended by the 
ACCF/AHA guidelines to obtain an EF measurement in patients who have had a significant 
change in clinical status, such as a hospitalization. However, this study found that only 56% of 
patients had an EF measurement within 1 month of the index HF admission, with an average lag 
time between EF measurement and HF admission of about 3.8 months. Owan et al found that 
76% of patients had an EF measurement within 1 month of an HF hospitalization,10 and a more 
recent study in patients at Kaiser Permanente found that only 34% of hospitalized HF patients 
had an echocardiogram and EF measurement during a HF admission.64 There seems to be a 
common trend of a large proportion of HF admissions lacking an associated EF measurement in 
retrospective database analyses. This reveals the potential for suboptimal practices, such as not 
ordering or documenting results of an echocardiogram for a hospitalized HF patient, or 
miscoding the principal diagnosis for admission. 
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In terms of healthcare resource utilization, results of this study showed that HF patients 
with preserved EF had significantly more primary care visits, but fewer cardiology visits, than 
those with reduced EF. These findings support those of Nichols et al., which found that HF 
patients with preserved EF incurred significantly more annualized outpatient visits and 
emergency room visits than those with reduced EF, despite small absolute differences.64 
Inpatient and pharmacy utilization did not differ in either study.  
Hospitalizations are common after an HF diagnosis. A study in Minnesota showed that 4 
out of 5 HF patients were hospitalized at least once, with over 40% hospitalized more than 4 
times throughout the study period.57 Desai et al. found that among 60% of HF patients who 
were hospitalized, those with a reduced EF had higher rates of cardiovascular-related 
hospitalization compared to those with a preserved EF.65 This study found that a vast majority 
(94%) of all patients had at least 1 re-hospitalization in the year following the index admission, 
with 25% having 5 or more hospitalizations. In support of existing literature, our findings 
suggest that although re-hospitalizations are common among HF patients, the patients’ EF has 
little impact on inpatient or pharmacy resource utilization in the year after an HF 
hospitalization. However, those with preserved EF seem to have more primary care visits and 
fewer cardiology-related encounters than those with reduced EF.  
We found that costs following a HF hospitalization, including inpatient, outpatient, 
pharmacy, and total costs, did not differ between the two groups, with total 1-year mean costs 
of about $12,000 after the index event. Similarly, the NHLBI Cardiovascular Health Study in 
2006 found that 5-year overall costs were similar between those with reduced versus preserved 
EF, ranging from $32,000 to $49,000, despite reduced EF patients having more cardiology visits 
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and cardiac procedures.56 However, the previously mentioned study did not stratify cost 
differences by healthcare segment (i.e., inpatient, outpatient, pharmacy, etc). 
This study found that HF patients with preserved EF had a higher prevalence of 
depression, and those with reduced EF had a higher prevalence of coronary heart disease and 
cardiomyopathy. The latter two support the fact that these are common etiologies of HF, as 
well as earlier findings that HF with reduced EF is associated with more coronary heart 
disease.10 Also, at 62%, we found that the prevalence of coronary heart disease in those with 
preserved ejection fraction was higher than what was previously reported, ranging from 36% to 
53% in the literature.56,64 
Previously, studies have identified differences in other comorbidities between the two 
groups.  For example, Steinberg et al showed that HF with preserved EF is associated with 
greater prevalence of hypertension, obesity, atrial fibrillation, diabetes, and anemia compared 
to those with reduced EF,11,15 and another study showed that HF patients with preserved EF 
had a higher risk of noncardiovascular death in comparison to those with reduced EF.22 These 
differences in comorbidities further highlight distinctive features between both groups, 
especially since guideline-recommended therapies of those with preserved EF are focused on 
treatment of comorbid conditions rather than the HF itself.12 
At baseline, a greater proportion of HF patients with reduced EF had antiarrhythmic use, 
while those with preserved EF had more use of calcium channel blockers. After adjusting for 
covariates, we found that HF with reduced EF remained predictive of less calcium channel 
blocker use after a HF hospitalization. This is not surprising, as clinical guidelines do not 
recommend routine use of calcium channel–blocking agents in HF with reduced EF.12 In 
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contrast, a Cardiovascular Research Network study found that HF patients with reduced EF 
were less likely to be treated with cardiac and HF therapies prior to their index HF event; 
however they were significantly more likely to be treated with new cardiac medications and HF 
therapies after their HF diagnosis compared to those with preserved EF.66 
Limitations 
 This study has several limitations. Retrospective analyses using claims data and 
electronic medical records may not include complete patient information and rationale behind 
clinical management of patients. In addition, prescription fills obtained via pharmacy claims 
only indicate that a patient picked up the medication, but does not confirm whether the patient 
has actually taken it. Comorbidities were obtained from diagnosis codes in medical claims, 
consequently were likely to be underestimated. Several HF index admissions did not have a 
recent EF measurement, thus placement of these patients in either study group was based on 
an outdated EF measurement. The small sample size of the study and the fact that not all 
subjects had a full two years of data also limit the interpretation of the results. Due to the 
chronic nature of HF and its associated long term sequelae, the 1-year follow-up period may 
not have provided adequate insight to long term outcomes and costs. Finally, the patient 
population is predominantly in rural Central Texas and may differ from the rest of Texas and the 
US, thereby potentially limiting the generalizability of the study.  
Conclusion 
As novel and costly therapies for HF are on the horizon, it is important to understand 
differences in healthcare utilization between patients with reduced versus preserved EF to 
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make informed decisions about allocation of resources. This study demonstrated that 
healthcare utilization and associated costs are similar between HF patients with reduced and 
preserved EF, thus HF can be considered a single entity in terms of overall resource use.   We 
also found that HF patients with reduced EF have higher prevalence of coronary heart disease 
and cardiomyopathy and less use of calcium channel blockers. Results of this study also suggest 
a need for improvement in obtaining an echocardiogram and EF measurement during an HF 
hospitalization, as recommended by clinical guidelines. Further research is needed to evaluate 
other outcomes, including potential differences in biomarkers such as brain natriuretic peptide, 
as well as cardiovascular events and mortality. These outcomes should also be assessed over a 
longer period of time to appropriately capture potential differences occurring in the long term.  
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